Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab + Lenalidomide vs Rituximab + Lenalidomide in Relapsed/Refractory Follicular Lymphoma
NCT04712097Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2021
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of mosunetuzumab in follicular lymphoma (FL), sponsored by Roche. Started Oct 2021; status: active, not recruiting.
02
Drugs
mosunetuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04712097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04712097.